Credit Suisse Ag Uro Gen Pharma Ltd. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Credit Suisse Ag holds 1,200,000 shares of URGN stock, worth $23 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,200,000
Previous 1,200,000
-0.0%
Holding current value
$23 Million
Previous $18 Million
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding URGN
# of Institutions
158Shares Held
39.6MCall Options Held
2.02MPut Options Held
702K-
Rtw Investments, LP New York, NY4.54MShares$87.2 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$61.3 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.48MShares$47.6 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$42.2 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$42.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $437M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...